JPRN-UMIN000022008已完成2 期
(C-SHOT1601)Phase II study of bortezomib plus Lenalidomide and dexamethasone (Once weekly BLd) for elderly or transplant-ineligible patients with untreated symptomatic multiple myeloma - (C-SHOT1601)Phase II study of Once weekly BLd therapy for elderly or transplant-ineligible patients with untreated symptomatic multiple myeloma
agoya City University Hospital Division of Hematology & Oncology0 个研究点目标入组 30 人开始时间: 2016年4月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) synchronous or metachronous malignancy 2) active infection 3) severe constipation or illeus 4) interstitial pneoumonia, pulmonary fibrosis 5) uncontrolled diabetes 6) inability to intake antithrombotic medication 7) pregnant or nursing women mellitus 8) uncontrollable hypertension 9) psychological disturbance 10) active double cancer 11) HBs-Ag positive or HCV-Ab positive or HIV-Ab positive 12) grade 3 or higher peripheral neuropathy, or grade 1 or higher neuralgia 13) glaucoma 14) primary plasma cell leukemia 15) no adminstration of blood transfusion or G-CSF within 7days befor the treatment 16) no evidence of cardiac or intestinal amyloidosis 17) allergic history to borate or mannitol
研究者
相似试验
已完成
1 期
Phase I/II study of bortezomib plus Lenalidomide and dexamethasone (Once weekly VRd-21) for relapsed and/or refractory multiple myeloma (Once weekly VRd-21, I/II VRD for MM)Proteasome inhibitor and immunomodulatory drug pre-treated relapsed and/or refractory multiple myeloma after two or more prior lines of chemotherapyJPRN-UMIN000013169agoya City University Hospital30
进行中（未招募）
不适用
Randomized phase II study of bortezomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in elderly patients with newly diagnosed multiplemyelomaKCT0004508Samsung Medical Center126
已完成
1 期
Phase I/II trial of subcutaneous bortezomib plus lenalidomide combined with dexamethasone combination therapy for relapsed or refractory multiple myeloma patientsMultiple myelomaJPRN-UMIN000013067Fukuoka Blood and Marrow Transplantation Group50
进行中（未招募）
不适用
Estudio de fase II con Bortezomib, Dexametasona y Rituximab en combinación, en pacientes con Macroglobulinemia de Waldenström (MW) sin tratamiento previo (Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom’s Macroglobulinemia) - protocol BDRMacroglobulinemia de Waldenström (MW) [Waldenstrom’s Macroglobulinemia]MedDRA version: 8.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaEUCTR2006-003563-31-ESRed Europea de Mieloma (European Myeloma Network)90
进行中（未招募）
1 期
A study in which is investigated if the medicine bortezomib is effective in patients with AL amyloidosisEUCTR2010-021445-42-NLHOVON Foundation50